CNS Pharmaceuticals, Inc. (CNSP) Stock

CNS Pharmaceuticals, Inc. (CNSP) is a Healthcare stock trading at $5.87 (as of 2026-08-21), with a market capitalization of $8.57M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CNS Pharmaceuticals, Inc. develops anti-cancer drug candidates targeting brain and central nervous system tumors, including Berubicin, which is being studied in Phase I and II clinical trials for glioblastoma multiforme. The company has entered licensing and development agreements with organizations including Houston Pharmaceuticals, The University of Texas M.D. Anderson Cancer Center, and WPD Pharmaceuticals.

Valuation — source: SEC EDGAR (first-party)
Price$5.87
Market Cap$8.57M
Price / Book0.47
FCF Yield-204.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$27687.00
Net Margin-68086.9%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderStonepine Capital Management, LLC ($145790.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORami Levin
Employees4
CountryUS
IPO Date2019-11-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Traws Pharma, Inc. (TRAW)
  • Soligenix, Inc. (SNGX)
  • GeoVax Labs, Inc. (GOVX)
  • Xenetic Biosciences, Inc. (XBIO)
  • Exicure, Inc. (XCUR)
  • Azitra, Inc. (AZTR)
  • Kairos Pharma, Ltd. (KAPA)
  • PMGC Holdings Inc. (ELAB)
CNSP earnings history · CNSP institutional & insider holders · CNSP KPIs & operating metrics · CNSP financials · CNSP investor presentations & press releases · CNSP SEC filings · CNSP peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.